creasing motility problems, although the prognosis is still poor with any direct laceration of muscle. 10 The use of botulinum toxin A may yield improved outcomes over observation or surgery alone by (1) facilitating single vision more rapidly, (2) preventing secondary contracture of the antagonist muscle during the healing period, and (3) minimizing the force generated against the partially transected muscle. 2, 7, 11 In patients with a complete abducens palsy, contracture of the medial rectus was found to occur as early as 3-4 weeks so that early intervention with botulinum toxin A is recommended. For this patient, botulinum toxin A injections were sufficient to result in resolution of the ocular deviation without the need for surgical intervention. Since Scott and colleagues' 12 first described use in an animal model in 1973, botulinum toxin A has been used for a variety of ophthalmic and nonophthalmic indications, with one of the earliest clinical uses for the treatment of strabismus. 13 Although botulinum toxin A generally is thought to be a temporary or adjuvant therapy, when used in the treatment of strabismus, it may result in a long-term change in ocular alignment. 13, 14 Scott and colleagues observed that even after horizontal motility, electromyography (EMG) amplitude, and velocity of saccades returned to normal, the induced strabismus remained. 12 Several explanations for this effect have been suggested including the reorganization of sarcomeres and preferential effects of botulinum toxin A on a subpopulation of extraocular muscle fibers. [14] [15] [16] [17] Regardless of mechanism, botulinum toxin A may lead to a permanent alteration in extraocular alignment even after the recovery of other aspects of the muscle's function. Additionally, the dose required for complete paralysis of the extraocular muscles does not appear to cause any significant systemic side effects. 18 Given the possibility of long-term ocular realignment and the scarcity of complications that occur with its use, botulinum toxin A should be considered as a first-line therapeutic option in cases of iatrogenically induced strabismus that do not meet other criteria for early surgical intervention. Treatment should occur early to prevent contracture of the antagonist muscle, and strabismus surgery may be considered at a later time if the results are only partial or temporary.
